Mednet Logo
HomeMedical Oncology
Medical Oncology

Medical Oncology

Physician insights on cancer treatment protocols, immunotherapy, targeted therapies, and clinical trial updates.

Recent Discussions

Do you utilize consolidative radiation for metastatic NSCLC lung cancer patients on maintenance immunotherapy?

1 Answers

Mednet Member
Mednet Member
Medical Oncology · UCSD Moores Cancer Center

Yes but please refer these patients for NRG-LU002 study which is directly addressing this important question.

In what settings is Fluciclovine (Axumin) PET/CT best utilized in prostate cancer?

1
1 Answers

Mednet Member
Mednet Member
Radiation Oncology · Loyola University Chicago Stritch School of Medicine

This is one of the key questions we'll have to deal with in prostate cancer, and I think it extends even past Fluciclovine. The development of the various modern molecular imaging modalities in prostate cancer has been an interesting phenomenon. In the U.S., Fluciclovine PET/CT was the first of the ...

How do you treat metastatic mesenchymal chondrosarcoma?

1 Answers

Mednet Member
Mednet Member
Medical Oncology · Dana-Farber Cancer Institute

Mesenchymal chondrosarcoma is a rare aggressive variant of chondrosarcoma that is treated like a Ewing sarcoma. As with all chemotherapy, the patient's performance status should be acceptable to proceed with the chemotherapy which can be difficult to tolerate. If confirmed to be mesenchymal chondros...

How do you decide between adjuvant TDM-1 and trastuzumab in breast cancer patients who have residual disease at time of surgery but were unable to complete the recommended neoadjuvant course?

1 Answers

Mednet Member
Mednet Member
Medical Oncology · Washington University School of Medicine

Since TDM1 is likely better tolerated than the standard neoadjuvant regimen, it would make sense to give adjuvant TDM1 if a patient had residual tumor following neoadjuvant chemotherapy that was discontinued early due to toxicity.

For patients with NSCLC with large primary tumors (ie T4) but no mediastinal nodal involvement who are found to have isolated oligometastatic disease in the brain, do you still consider definitive management of the primary lung tumor?

1
1 Answers

Mednet Member
Mednet Member
Medical Oncology · University of Virginia

Interesting question! Particularly since T4N0M1 NSCLC is a relatively rare clinical scenario. First, what is the appropriate management of T4N0M0 lesions? Historically, these patients were considered unresectable and were classified as stage IIIB. Even with improvement in surgical techniques, resec...

When do you consider using high dose IL-2 in patients with mRCC?

2
2 Answers

Mednet Member
Mednet Member
Medical Oncology · Vanderbilt-Ingram Cancer Center

There were patients in the earlier Ipi/nivo phase 2 experience who were IL-2 failures and responded to Ipi/nivo, raising the hypothesis that the mechanism of response is not entirely overlapping. Thus, I believe HD IL-2 could still have a role even with modern combos, but will be used sparingly give...

For a patient with unresectable EGFR positive lung adenocarcinoma treated with chemoradiation and a single site of oligometastasis treated definitively, would you consider durvalumab as per PACIFIC study or EGFR-directed therapy?

1
1 Answers

Mednet Member
Mednet Member
Medical Oncology · UCSD Moores Cancer Center

Technically, this is metastatic disease so I would do osimertinib here. I would avoid antiPD1 in known EGFR in metastatic setting due to pneumonitis risk when you have to start the EGFRi eventually

What is your preferred neoadjuvant chemotherapy course for healthy adult patients with osteosarcoma?

1
3 Answers

Mednet Member
Mednet Member
Medical Oncology · Oregon Health & Science University

This article discusses the safety & efficacy of HDMTX in young adults and shows it can be safely administered, with good supportive care. The EURO-BOSS study is also a great resource for this topic.Because older adults do seem to tolerate HDMTX more poorly and experience markedly delayed clearance, ...

How many cycles of docetaxel do you give to patients with metastatic castration resistant prostate cancer?

3
1 Answers

Mednet Member
Mednet Member
Medical Oncology · Allegheny General Hospital-Western Pennsylvania Hospital

Toxicity with Neuropathy can be a major problem in the elderly population.

Would you consider HRT in a young woman (<35 years old) with gBRCA mutated TNBC who underwent bilateral mastectomies and BSO?

3
2 Answers

Mednet Member
Mednet Member
Medical Oncology · Valley Med Onc

I would use HRT for the beneficial effects of bone preservation, lipid improvement, sexual function, and quality of life. My preference is for women to have a concurrent hysterectomy with the BSO so the HRT can be estrogen alone, which has little, if any, risk for promoting breast cancer. In the les...